Physician profile
George Small
NPI 1821099011
$61,341.56
in general payments reported to CMS, 2019-2025
19 companies · $5,056 in 2025
The $5,056 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,826 · 2020: $4,436 · 2021: $16K · 2022: $16K · 2023: $7,630 · 2024: $7,602 · 2025: $5,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,091 · Travel and Lodging: $24.12 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,150.00 |
| Food and Beverage | $3,091.46 |
| Travel and Lodging | $24.12 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $55,382.60 | 2019-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $2,159.34 | 2021-2025 | Amvuttra, Onpattro |
| Genzyme Corporation | $1,047.70 | 2019-2021 | |
| Abbvie INC. | $927.76 | 2022-2025 | Ubrelvy, Qulipta |
| Argenx US, INC. | $419.08 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $360.78 | 2019-2021 | |
| Ucb, INC. | $253.09 | 2023-2024 | Zilbrysq |
| Saol Therapeutics INC. | $225.00 | 2021 | |
| Janssen Biotech, INC. | $157.45 | 2025 | |
| Biogen, INC. | $121.36 | 2021-2025 | Vumerity |
| Astrazeneca Pharmaceuticals LP | $103.08 | 2025 | Wainua |
| Genentech, INC. | $99.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $34.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2025 | Hyqvia |
| Eisai INC. | $22.43 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.